share_log

Bristol-Myers Squibb | DEF 14A: Definitive information statements

Bristol-Myers Squibb | DEF 14A: Definitive information statements

施贵宝 | DEF 14A：股东委托书决议
SEC announcement ·  03/28 22:39
Moomoo AI 已提取核心信息
Bristol-Myers Squibb (BMS) announced the upcoming virtual Annual Meeting of Shareholders scheduled for May 7, 2024. Shareholders of record as of March 14, 2024, are entitled to vote on several key proposals, including the election of 10 board directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as the independent auditor for 2024, and an amendment to the Certificate of Incorporation for limited officer exculpation. Additionally, two shareholder proposals will be considered, one advocating for an independent Board Chair and another on executive stock retention. The Board recommends votes for all directors, executive compensation, auditor ratification, and the charter amendment, but against the shareholder proposals. The meeting will also address the CEO transition, with Dr. Christopher Boerner taking over as CEO and Board Chair following Dr. Giovanni Caforio's retirement. The company's proxy materials, including this announcement, are available as of March 28, 2024.
Bristol-Myers Squibb (BMS) announced the upcoming virtual Annual Meeting of Shareholders scheduled for May 7, 2024. Shareholders of record as of March 14, 2024, are entitled to vote on several key proposals, including the election of 10 board directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as the independent auditor for 2024, and an amendment to the Certificate of Incorporation for limited officer exculpation. Additionally, two shareholder proposals will be considered, one advocating for an independent Board Chair and another on executive stock retention. The Board recommends votes for all directors, executive compensation, auditor ratification, and the charter amendment, but against the shareholder proposals. The meeting will also address the CEO transition, with Dr. Christopher Boerner taking over as CEO and Board Chair following Dr. Giovanni Caforio's retirement. The company's proxy materials, including this announcement, are available as of March 28, 2024.
百时美施贵宝（BMS）宣布即将于2024年5月7日举行的虚拟年度股东大会。截至2024年3月14日，登记在册的股东有权对几项关键提案进行投票，包括选举10名董事会董事、关于高管薪酬的咨询投票、批准德勤会计师事务所作为2024年独立审计师以及对有限高管人员免责的公司注册证书修正案。此外，将考虑两项股东提案，一项主张独立董事会主席，另一项提倡保留高管股票。董事会建议投票支持所有董事、高管薪酬、审计师批准和章程修正案，但反对股东提案。会议还将讨论首席执行官的过渡问题，乔瓦尼·卡福里奥博士退休后，克里斯托弗·博尔纳博士将接任首席执行官兼董事会主席。该公司的代理材料，包括本公告，将于2024年3月28日公布。
百时美施贵宝（BMS）宣布即将于2024年5月7日举行的虚拟年度股东大会。截至2024年3月14日，登记在册的股东有权对几项关键提案进行投票，包括选举10名董事会董事、关于高管薪酬的咨询投票、批准德勤会计师事务所作为2024年独立审计师以及对有限高管人员免责的公司注册证书修正案。此外，将考虑两项股东提案，一项主张独立董事会主席，另一项提倡保留高管股票。董事会建议投票支持所有董事、高管薪酬、审计师批准和章程修正案，但反对股东提案。会议还将讨论首席执行官的过渡问题，乔瓦尼·卡福里奥博士退休后，克里斯托弗·博尔纳博士将接任首席执行官兼董事会主席。该公司的代理材料，包括本公告，将于2024年3月28日公布。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息